Aquestive Therapeutics to Showcase Data on Anaphylm Epinephrine Sublingual Film at AAAAI Annual Meeting
Aquestive Therapeutics, a leading pharmaceutical company, is set to present findings from the investigational use of Anaphylm, their epinephrine sublingual film, at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The event is scheduled to take place from February 28 to March 3, 2025, in San Diego, CA.
About Anaphylm and Severe Allergic Reactions
Anaphylm is a potential new treatment option for severe allergic reactions, including anaphylaxis. Anaphylaxis is a life-threatening condition that occurs when the immune system overreacts to an allergen, leading to symptoms such as hives, swelling, difficulty breathing, and a rapid heart rate. Traditional epinephrine auto-injectors can be challenging to use in emergency situations, as they require proper injection technique and may cause anxiety and pain.
Presentations at AAAAI Annual Meeting
Several presentations will be given at the AAAAI Annual Meeting, showcasing the potential benefits of Anaphylm. These presentations include:
- Poster Session: “Efficacy and Safety of Anaphylm, a Sublingual Epinephrine Film, for the Treatment of Anaphylaxis: A Multicenter, Open-Label, Proof-of-Concept Study”
- Oral Abstract Session: “Real-World Experience with Anaphylm: A Prospective, Multicenter, Open-Label Study of the Use of a Sublingual Epinephrine Film for the Treatment of Anaphylaxis”
- Poster Session: “Characterization of Anaphylm: In Vitro Dissolution and Stability Studies”
Impact on Individuals
For individuals with severe allergies, the availability of a new, easy-to-use treatment option like Anaphylm could be a game-changer. The sublingual film eliminates the need for proper injection technique and reduces the anxiety and pain associated with traditional epinephrine auto-injectors. Additionally, the film’s fast dissolution and stability make it a promising alternative for those who need quick relief in emergency situations.
Impact on the World
The potential impact of Anaphylm on the world goes beyond individual patients. An estimated 300,000 people in the United States experience anaphylaxis each year, and approximately 2,000 deaths are attributed to this condition. With Anaphylm, emergency medical services (EMS) personnel and first responders could potentially administer the treatment more quickly and easily, potentially saving lives. Furthermore, the convenience and ease of use of Anaphylm may encourage more people with allergies to carry a treatment option with them at all times, reducing the risk of severe reactions.
Conclusion
Aquestive Therapeutics’ Anaphylm epinephrine sublingual film is poised to make a significant impact on the treatment of severe allergic reactions, including anaphylaxis. With several presentations at the AAAAI Annual Meeting showcasing the film’s efficacy, safety, and ease of use, this innovative delivery technology could offer a new, life-saving option for individuals with allergies and those who respond to allergens with severe reactions. The potential benefits of Anaphylm extend beyond individual patients, as improved treatment options could save lives and encourage more people to carry emergency treatments with them at all times.
